Prognosis, disease progression, and treatment of atrial fibrillation patients during 1 year: Follow-up of the Euro Heart Survey on Atrial Fibrillation
Închide
Conţinutul numărului revistei
Articolul precedent
Articolul urmator
177 5
Ultima descărcare din IBN:
2023-09-13 15:23
SM ISO690:2012
NIEUWLAAT, Robby, PRINS, Martin H., LE-HEUZEY, Jean Yves F., NOI, Autori, VATAMAN, Eleonora, GROSU, Aurel. Prognosis, disease progression, and treatment of atrial fibrillation patients during 1 year: Follow-up of the Euro Heart Survey on Atrial Fibrillation. In: European Heart Journal, 2008, vol. 29, pp. 1181-1189. ISSN 0195-668X. DOI: https://doi.org/10.1093/eurheartj/ehn139
EXPORT metadate:
Google Scholar
Crossref
CERIF

DataCite
Dublin Core
European Heart Journal
Volumul 29 / 2008 / ISSN 0195-668X

Prognosis, disease progression, and treatment of atrial fibrillation patients during 1 year: Follow-up of the Euro Heart Survey on Atrial Fibrillation

DOI:https://doi.org/10.1093/eurheartj/ehn139

Pag. 1181-1189

Nieuwlaat Robby1, Prins Martin H.1, Le-Heuzey Jean Yves F.2, Noi Autori, Vataman Eleonora3, Grosu Aurel3
 
1 University Hospital Maastricht,
2 European Hospital Georges Pompidou, Paris,
3 Institute of Cardiology
 
 
Disponibil în IBN: 19 iunie 2023


Rezumat

Aims: To gain insight in the prognosis and treatment of atrial fibrillation (AF) patients during 1-year follow-up in the Euro Heart Survey (EHS) on AF. Methods and results: The EHS enrolled 5333 AF patients in 2003-2004. One-year follow-up data were available for 80%. Of first detected AF patients, 46% did not have a recurrence during 1 year, paroxysmal AF largely remained paroxysmal AF (80%), and 30% of persistent AF progressed to permanent AF. Many treatment changes occurred since baseline. Oral anticoagulation was started in 19% and discontinued in 16% of all patients. Of patients initially on rhythm control 27% did not receive rhythm control during follow-up, whereas 15% of patients initially on rate control received rhythm control. Mortality was highest in permanent AF (8.2%), but also substantial in first detected AF (5.7%). In multivariable analysis, sinus rhythm at baseline was associated with lower mortality, but no significant effect was observed regarding the application of either rhythm or rate control. Conclusion: The EHS on AF provides unique prospective observational data on AF progression, long-term treatment, prognosis, and determinants of adverse outcome of the total clinical spectrum of AF in a European cardiology-based patient cohort.

Cuvinte-cheie
Anticoagulation, atrial fibrillation, management, mortality, prognosis, progression, Rate control, Rhythm control